PepGen (PEPG)

• Market cap: $118M
• 1 day: -11.25%
• 5 days: 25.17%
• 1 month: -17.50%
• 3 months: -60.54%
• 6 months: -78.39%
• Year to date: -48.80%
• 1 year: -44.15%
• 5 years: -71.84%
• 10 years: -71.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Employees: 76

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

2% more funds holding

Funds holding: 61 [Q2] → 62 (+1) [Q3]

8% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 13

0.08% more ownership

Funds ownership: 77.66% [Q2] → 77.74% (+0.08%) [Q3]

46% less capital invested

Capital invested by funds: $402M [Q2] → $217M (-$185M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 65% upside
• Avg. target: $14.67 304% upside
• High target: $26 616% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

B of A Securities Tazeen Ahmad 39% 1-year accuracy 11 / 28 met price target	65% upside $6	Neutral Maintained	18 Nov 2024
Wedbush Laura Chico 32% 1-year accuracy 20 / 62 met price target	231% upside $12	Outperform Maintained	8 Nov 2024
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target	616% upside $26	Buy Reiterated	8 Nov 2024